Increased development costs have forced the pharmaceutical industry to adopt new strategies to maximize the value of their pipeline. In this context, combination therapies provide an appealing alternative to drug development from scratch, both in terms of cost and clinical performance.
What are combination therapies useful for?
Combination therapies represent an interesting opportunity for pharmaceutical companies to ensure higher returns from their R&D investment.
- Overcoming the resistance to treatment
- Maximizing therapeutic outcome in complex diseases
- Improving the clinical profile of drugs in your pipeline
- Rescuing failed candidates or extending the commercial life of out-of-patent drugs
What does Anaxomics offer?
Screening drug combinations by trial and error is impractical due to the sheer amount of possible permutations.
To avoid this inconvenience, Anaxomics employs its Therapeutic Performance Mapping System (TPMS) proprietary technology to identify potential combination therapies under the prism of systems biology. TPMS simulates human life in the form of a protein network that contains all the available knowledge about diseases and drug targets, and consequently is able to detect the best drug combinations to elicit the desired outcome.
Anaxomics’ TPMS adds value to your research by:
Combining the drug of interest with the standard of care or other therapies in your pipeline to:
- Increase the efficacy
- Improve the safety
- Overcome drug resistance.
Identifying revolutionary mechanisms of action for combinations that modulate simultaneously various aspects of a complex disease: additive, antagonistic or synergistic effects
Gimenez, N., R. Tripathi, A. Giró, L. Rosich, M. López-Guerra, I. López-Oreja, H.
F. Arenas, J. M. Mas, P. Pérez-Galán, J. Delgado, E. Campo, J. Farrés and D.
Colomer (2020). Systems
biology drug screening identifies statins as enhancers of current therapies in chronic
Sci Rep, 10(1): p. 22153.
Villalba, A. , S. Rodriguez-Fernandez, D. Perna-Barrull, R. M. Ampudia, L. Gomez-Muñoz, I.
Pujol-Autonell, E. Aguilera, M. Coma, M. Cano-Sarabia, F. Vázquez, J. Verdaguer and M. Vives-Pi
(2020). Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic
Pancreatic Cell Reprogramming.
Front Endocrinol (Lausanne) 11: 258.